Arbutus Biopharma Corp (ABUS, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus Biopharma Corp has a market cap of $291.650 million; its shares were traded at around $5.25 with and P/S ratio of 26.92.
For the last quarter Arbutus Biopharma Corp reported a revenue of $2.53 million, compared with the revenue of $-0.20 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $10.7 million, an increase of 617.6% from last year. For the last five years Arbutus Biopharma Corp had an average revenue decline of 20.2% a year.
The reported loss per diluted share was $1.56 for the year, compared with the loss per share of $0.92 in the previous year. The Arbutus Biopharma Corp had an operating margin of -1036.45%, compared with the operating margin of -32973.78% a year before. The 10-year historical median operating margin of Arbutus Biopharma Corp is -102.68%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Arbutus Biopharma Corp has the cash and cash equivalents of $54.3 million, compared with $23.4 million in the previous year. The long term debt was $12.0 million, compared with $12.0 million in the previous year. Arbutus Biopharma Corp has a financial strength rank of 4 (out of 10).
At the current stock price of $5.25, Arbutus Biopharma Corp is traded at 404.8% premium to its historical median P/S valuation band of $1.04. The P/S ratio of the stock is 26.92, while the historical median P/S ratio is 5.36. The stock gained 90.91% during the past 12 months.
For the complete 20-year historical financial data of ABUS, click here.